^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    oxaliplatin

    i
    Other names: 1 OHP, 1670 RB, L OHP, NSC 266046, PR 54780, RP 54780, SR 96669, 1670 RB7
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, DNA cross linking agent
    Related drugs:
    15h
    MAST: A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=66, Terminated, Imugene Limited | N=100 --> 66 | Trial completion date: Nov 2026 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jan 2026; Portfolio prioritization
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • VAXinia (CF33-hNIS)
    15h
    QYFYEC2024-181: Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01） (clinicaltrials.gov)
    P2, N=35, Recruiting, The Affiliated Hospital of Qingdao University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    16h
    Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA (clinicaltrials.gov)
    P2, N=40, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Yidafan (ivonescimab)
    16h
    Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer (clinicaltrials.gov)
    P2, N=46, Completed, Yale University | Active, not recruiting --> Completed
    Trial completion
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    16h
    Cryotherapy & Oxaliplatin (clinicaltrials.gov)
    P=N/A, N=40, Suspended, NYU Langone Health | Trial completion date: Jun 2026 --> Jun 2027 | Recruiting --> Suspended | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial suspension • Trial primary completion date
    |
    oxaliplatin
    23h
    TRIUNITE06: LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
    New P1 trial
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    23h
    A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (clinicaltrials.gov)
    P3, N=614, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • setidegrasib (ASP3082) • Onivyde (nanoliposomal irinotecan) • levoleucovorin calcium
    1d
    NEOASIS: Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (clinicaltrials.gov)
    P2/3, N=133, Recruiting, The Netherlands Cancer Institute | N=92 --> 133
    Enrollment change • Pan tumor
    |
    MSI-H/dMMR
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    1d
    Pathological complete response in microsatellite- stable gastric cancer with liver and bulky lymph node metastases after nivolumab-based chemotherapy and surgery: a case report. (PubMed, Front Immunol)
    Herein, we present a case of advanced MSS gastric cancer with liver and bulky lymph node metastases, in which combination therapy with S-1 plus oxaliplatin (SOX) and nivolumab led to a pathological complete response...This case illustrates that even in MSS gastric cancer with low TMB levels, exceptionally high PD-L1 expression may predict a profound response to ICI-based therapy. The PD-L1 CPS may serve as a critical biomarker independent of TMB or microsatellite-instability status.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • TP53 mutation • PD-L1 overexpression • TMB-L
    |
    Opdivo (nivolumab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    1d
    Investigating Genetic Risk to Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Colorectal Cancer Through Routinely Available NGS Data. (PubMed, Mod Pathol)
    These findings highlight the utility of expanded analysis of routinely obtained NGS panel results at the time of CRC diagnosis at many medical centers to personalize the chemotherapy regimen. Our data suggest that patients who carry the ERCC1 rs11615 (A>G) variant may be protected from developing oxaliplatin-induced SOS and those lacking the G allele should be monitored more carefully after oxaliplatin use.
    Journal • Next-generation sequencing
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ERCC1 (Excision repair cross-complementation group 1) • ERCC2 (Excision repair cross-complementation group 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • GSTP1 (Glutathione S-transferase pi 1) • MTHFR (Methylenetetrahydrofolate Reductase) • ABCC2 (ATP Binding Cassette Subfamily C Member 2) • DPYD (Dihydropyrimidine Dehydrogenase) • GSTM1 (Glutathione S-transferase mu 1) • GSTT1 (Glutathione S-transferase theta 1)
    |
    oxaliplatin
    1d
    Impact of Germline BRCA Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis. (PubMed, JCO Precis Oncol)
    gBRCA mutation status was strongly associated with enhanced radiologic and biological responses to mFFX in APC. Routine screening for gBRCA mutations may provide essential guidance in therapeutic decision making and substantially improve clinical outcomes in this population.
    Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset) • CA 19-9 (Cancer antigen 19-9)
    |
    BRCA mutation
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    1d
    SCAR: Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Zhejiang University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    capecitabine • oxaliplatin • Hetronifly (serplulimab) • celecoxib oral